Sistemic has introduced the Companion Biomarker program to simplify the benefits of miRNA (micro RNA) analysis and profiling to support decision making in the clinical research sector.
The company said drug discovery organisations will be able to utilise multiple miRNA biomarkers to determine the efficacy of targeted drugs in major therapeutic areas and when developing companion biomarker strategies for future clinical development.
Companion biomarkers are the most recent extension of miRNA profiling technology and are expected to provide valuable clinical data to guide both pre-clinical and clinical studies.
The system will use the robustness and specificity of miRNA to identify highly discriminatory biomarkers that in turn will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.
